ReCor Medical Names Lara Barghout as President and Chief Executive Officer

January 3, 2023—ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., announced the appointment of Lara Barghout as President and Chief Executive Officer of ReCor.

Ms. Barghout will lead the ReCor business strategy and organization in the global commercialization of the company’s Paradise ultrasound renal denervation (uRDN) system for the treatment of hypertension. The Paradise uRDN system has received CE Mark approval for the treatment of hypertension in Europe and is an investigational device in the United States and Japan.

According to the company, Ms. Barghout joins ReCor from Siemens Healthineers, where she was Senior Vice President and Head of Advanced Therapies, leading the image-guided therapy business in North America. Previously, Ms. Barghout held several escalating roles at Terumo Cardiovascular, including Senior Vice President, Global Commercial Operations.

Ms. Barghout succeeds Andrew Weiss, who joined ReCor in 2013 and led the company during the development of the Paradise uRDN system through early clinical trials, the acquisition of ReCor by Otsuka in 2018, the RADIANCE trial, and the recent submission to the FDA for premarket approval.

On November 29, 2022, the company announced the submission of the premarket approval application to the FDA for the Paradise uRDN system. ReCor has begun the GPS (Global Paradise System) registry in the European Union, with plans to expand globally.